Heart transplantation after Fontan operation

Igor E. Konstantinov, MD, PhD, FRACS, Antonia Schulz, MD, and Edward Buratto, MBBS, PhD, FRACS

There is an increasing number of long-term survivors with complex congenital heart disease (CHD) and single ventricle palliation, adding to a growing cohort of patients with a Fontan circulation. In the modern era, survival at 20 years is greater than 90%. However, it appears that the fate of most patients who are palliated in this manner is to eventually develop failure of the single ventricle or the Fontan circulation. Currently, the ultimate treatment for the failed Fontan circulation is cardiac transplantation. Patients with failed Fontan circulation make up an increasing proportion of those presenting for heart transplantation. The need for expert surgical management of these complex patients with failing Fontan circulation has become increasingly clear during recent years.

THE FAILING FONTAN CIRCULATION

Overall, the incidence of Fontan failure is 26% to 30% at 20 years, and an underlying diagnosis of hypoplastic left heart syndrome (HLHS) has been identified as a primary risk factor. Failure of the Fontan circulation may occur in patients with impaired or preserved ventricular function. Of note, most of the patients with failed Fontan circulation have preserved ventricular function. As survival of the multistage palliation for HLHS continues to improve, the proportion of patients with Fontan circulation and HLHS is increasing. For instance, in 1290 patients in Australia and New Zealand who underwent the Fontan operation from 1995 to 2020, there was a dramatic proportional increase in patients with HLHS, reaching 25% for the most recent 5-year period (Figure 1). At some institutions, HLHS may be as prevalent as 50% in patients with Fontan circulation. It was previously demonstrated that right ventricular dominance is a risk factor for the failure of Fontan circulation.

Thus, such an increase will inevitably lead to a higher proportion of patients having failure of the Fontan circulation, and subsequently being referred for transplantation. Most important, the technical complexity of transplantation in patients after Norwood-type aortic reconstruction is greater compared with that in other types of Fontan circulation.

CENTRAL MESSAGE

The growing number of patients with failing Fontan circulation necessitates urgent development of a multidisciplinary model of expert care to address the perioperative complexity of heart transplantation.
of patients with other forms of CHD. In short, no patient options. Most important, long-term survival after heart licence where they can be assessed for all available treatment early referral for transplant evaluation at a center of excel-

patients. Patients with failing Fontan circulation require lines for assessment and management for these challenging patients. Patients with failing Fontan circulation in Australia and New Zealand.

FIGURE 1. Increased proportion of patients with HLHS in 1290 survivors with Fontan circulation in Australia and New Zealand. HLHS, Hypoplastic left heart syndrome.

become clear during recent years. An analysis of the Australia and New Zealand Fontan registry has demonstrated that only 2.5% of 1369 patients with Fontan circulation underwent transplantation at 20 years, whereas there was a higher proportion of patients with Fontan circulation failure. Furthermore, evaluation of referral patterns revealed that patients who were not treated at the national referral center were less likely to be considered for transplantation. This indicates the need for standardized guidelines for assessment and management for these challenging patients. Patients with failing Fontan circulation require early referral for transplant evaluation at a center of excellence where they can be assessed for all available treatment options. Most important, long-term survival after heart transplantation in Fontan patients is not different than that of patients with other forms of CHD. In short, no patient with failing Fontan circulation should be considered unfit for heart transplantation until appropriately assessed by the multidisciplinary group with combined expertise in surgical management of complex CHD, durable ventricular assist device (VAD) support, and heart transplantation.

CANDIDACY FOR TRANSPLANTATION
Perhaps the best way to determine if the multiorgan failure is reversible would be to support failing Fontan circulation with durable VAD, which could be of various configurations (Figure 2). Although most commonly one durable VAD is used to support systemic or pulmonary circulation, “biventricular” support can be used in rare cases, although the latter appears unnecessary in most patients. In many patients, end-organ dysfunction would be reversible with VAD support as a bridge to candidacy. Our group has previously demonstrated that the need for inotropic support and worsening renal function were predictors for death or delisting due to deterioration in children awaiting heart transplantation, yet they can be successfully bridged with VAD to heart transplantation. Needless to say, the configuration of VAD support must be tailored to the mode of Fontan failure and the procedure must be performed by a surgeon with expertise in managing patients with univentricular circulation. In particular, patients with preserved ventricular function often have a substantial burden of aortopulmonary collaterals and higher pulmonary vascular resistance, and appear to have increased mortality compared with patients with impaired function.

Multiorgan dysfunction, especially renal and liver failure and plastic bronchitis, commonly occurs in the failing Fontan circulation. Although reasonable results have been reported for combined heart-liver transplantation, the indications for liver transplantation in Fontan-associated liver disease still need to be defined, and the benefit of such an approach remains unclear. However, with appropriate VAD support it is possible that improvement in liver function would occur in many patients, allowing heart transplantation to be performed in a more stable patient and minimizing the need for liver transplantation. Because this is a rapidly evolving field, there are still many unknowns, and currently there are limited data to support this notion. Likewise, heart-lung transplantation may be considered in patients with hypoplastic pulmonary arteries and pulmonary hypertension, yet a period of cavopulmonary VAD (Figure 2, B and E) support may result in significant improvement of pulmonary artery arborization and lowering of pulmonary resistance. The is exemplified by our recent Fontan patient with normal systolic function of the single ventricle and severe plastic bronchitis and protein-losing enteropathy. This 5-year-old girl could not be weaned off ventilatory support and deteriorated rapidly, requiring urgent extracorporeal membrane oxygenator support. In this state, the patient was not a candidate for heart transplantation. Cavopulmonary VAD insertion (Figure 2, B) resulted in complete resolution of protein-losing enteropathy and plastic bronchitis. She is has been supported by VAD for 588 days until she underwent successful heart transplantation. We and others have previously emphasized this approach as a bridge to candidacy for heart transplantation in patients with failing Fontan circulation and preserved single ventricle function. Yet, the current world experience is still limited to a handful of patients. Although a combined heart-lung-liver transplantation is technically feasible, the need for such procedure.
may be reduced in Fontan patients with appropriate VAD support.

TECHNICAL ASPECTS OF TRANSPLANTATION AFTER FONTAN OPERATION

We have previously reported that in patients undergoing heart transplantation after the Fontan in Australia and New Zealand, aortic arch reconstruction was required in 9% of patients and pulmonary artery reconstruction in 53%. As the proportion of Fontan patients with HLHS is steadily increasing, we expect that many more patients will require complex reconstruction of the aortic arch and pulmonary arteries. In fact, others have reported rates of up to 85.4% for pulmonary artery reconstruction. After Norwood-type reconstruction of the aortic root (Figure 3, A), the enlarged aortic root, the pulmonary artery, particularly after pulmonary artery stenting, and often the innominate vein are so densely adherent that they can only be removed en bloc, resulting in the need to reconstruct major vessels (Figure 3, B). This complexity can be compounded by heterotaxy syndromes, including azygos continuation of the inferior vena cava. Thus, it is crucial to achieve reconstruction of aortic arch (Figure 3, C1), pulmonary arteries (Figure 3, C2), and systemic venous drainage (Figure 3, C3) before arrival of the donor heart to minimize ischemic time. The systemic venous reconstruction can be achieved using donor
FIGURE 3. Complexity of surgical preparation for heart transplantation in patients with HLHS after Fontan operation. A, Enlarged aortic root after initial aortic reconstruction often compresses the pulmonary artery, and the latter may require stenting. Thus, anatomic separation of the aortic arch is often impossible, and the aortic arch replacement is required. B, In addition to reconstruction of aortic arch and central pulmonary arteries, patients with heterotaxy and anomalous systemic venous drainage require reconstruction of systemic venous pathways. C, Sequential reconstruction of aortic arch (C1), central pulmonary arteries (C2), and systemic venous drainage (C3) must be accomplished before arrival of the heart to minimize ischemic time of the donor heart. D, After heart transplantation, meticulous hemostasis is required to minimize bleeding from the numerous suture lines and ensure judicious use of blood products. L SVC, Left superior vena cava; R SVC, right superior vena cava; R P A, right pulmonary artery; L PA, left pulmonary artery; V AD, ventricular assist device; A o, aorta; I V C, inferior vena cava.
innominate vein. Although it may appear tempting to use donor aorta and branch pulmonary arteries for reconstruction during heart transplantation, such temptation should be resisted, because it always takes longer than anticipated to reconstruct aorta and fragile pulmonary arteries, especially after stent removal. The pulmonary arteries and systemic veins can be reconstructed with prosthetic material or a homograft before donor heart arrival. Thus, the entire reconstruction is completed before transplantation (Figure 3, D).

The aortic reconstruction must be planned in advance because this is the first crucial step of the vascular reconstruction before transplantation. Aortic arch reconstruction is often required after Norwood-type aortic repair and can be achieved using a vascular prosthesis.24-27 We have previously reported a rate of 75% for reconstructions of the great vessels after previous univentricular palliation.27 In particular, in our experience, 50% of patients with prior Norwood-type reconstruction required aortic arch reconstruction.27 Reconstruction of the aortic arch should be performed before arrival of the donor heart to minimize ischemic time. This is achieved using hypothermia with continuous cerebral and lower body perfusion (Figure 4).

In contrast, transplantation in patients without prior Norwood-type aortic root reconstruction (eg, in those with tricuspid atresia) is easier because it does not usually require aortic arch replacement. In these patients, the use of donor central pulmonary arteries25 or donor descending aortic interposition graft for repair of pulmonary artery discontinuity can be considered.28 Likewise, a donor innominate vein can be used in this setting to reconstruct systemic venous return.

In patients with situs inversus or heterotaxia, more complex pretransplantation vascular reconstruction may result in significantly longer cardiopulmonary bypass times.12,25 In these patients, a graft may be used to reconstruct systemic venous return before the donor heart arrives. The

![FIGURE 4. Aortic reconstruction after en bloc removal of the ascending aorta, aortic arch, and pulmonary arteries. A, A graft sutured to the femoral artery is cannulated. After hypothermia is achieved, the ascending aortic cannular is introduced into the innominate artery and the arch branches are snagged. B, A balloon catheter is introduced into the descending aorta via the graft so that a continuous lower body perfusion is maintained in addition to cerebral perfusion. C, Once left common carotid and left subclavian arteries are anastomosed, the balloon catheter is removed, the aorta is crossclamped between the carotid arteries and the antegrade perfusion of the whole body is reestablished. Once the innominate artery is reanastomosed, the aortic crossclamped is repositioned onto ascending aorta. If the time permit, while awaiting for the donor heart to arrive, the femoral artery can be reconstructed at this stage.](image-url)
| First author | Publication year | Study time frame | Fontan patients | Age (y) | HLHS | Early mortality | Long-term survival |
|--------------|------------------|------------------|----------------|---------|------|-----------------|-------------------|
| Gamba 32     | 2004             | 1990-2002        | 14             | 17.2 ± 6.3 | None | 14.3%          | 86% (1 y) 77% (5 y) 62% (10 y) |
| Bernstein 30 | 2006             | 1993-2001        | 70             | 10.7 ± 5.4 | Not reported | Not reported | 77% (1 y) 73% (3 y) 67% (5 y) |
| Kanter 13    | 2011             | 1988-2010        | 27             | 8.2 ± 5.0  | NA   | 3.7%           | 81.5% (1 y) 65.5% (5 y) |
| Voeller 2    | 2012             | 1986-2009        | 34             | Not reported for Fontan | Not reported | 23.5% | 55.6% (10 y) |
| Davies 12    | 2012             | 1984-2007        | 43             | 14.5 (1-47) | 14.6% | 25%            | 62.4% (1 y) 58.7% (5 y) 47.5% (10 y) |
| Karamlou 45  | 2012             | 1993-2007        | 144            | 25.4 ± 10.9 | Not reported | 23% | Not reported |
| Backer 46    | 2013             | 1990-2012        | 22             | 14.9 ± 11.8 | 27.3% | 23%            | 77% (1 y) 66% (5 y) 45% (10 y) |
| Iyengar 27   | 2014             | 1988-2012        | 8              | 12.4 ± 6.1  | 50%   | 0%             | Not reported for Fontan |
| Michielon 31 | 2014             | 1991-2011        | 61             | 15 ± 9.7   | 26.2% | 18.3%          | 81.9% (1 y) 73% (5 y) 56.8% (10 y) |
| Shi 3        | 2016             | 1990-2015        | 34             | 17 (11-31)  | 18%   | 5.8%           | 91% (1 y) 78% (5 y) 71% (10 y) |
| Murtuza 5    | 2016             | 1990-2015        | 26             | 26.1 ± 8.6  | None  | 30.8%, 23.8% (recent era) | 65.4% (1 y) 65.4% (1 y) |
| Miller 47    | 2016             | 1995-2014        | 47             | 13 ± 6     | Not reported | Not reported | early era: 63% (1 y) recent era: 90% (1 y) |
| Tabarsi 33   | 2017             | 1984-2013        | 351            | 14 (7-24)  | 18.3% | Not reported | 80.3% (1 y) 71.2% (5 y) |
| Simpson 38   | 2017             | 1993-2014        | 402*           | 10.5 ± 4.9 | Not reported | Not reported | recent era: 89% (1 y) 85% (3 y) 78% (5 y) early era: 77% (1 y) 74% (3 y) 72% (5 y) 64% (10 y) 42% (15 y) |
| Berg 44      | 2017             | 1991-2014        | 36             | 21.3 (7.2-48.1) | 28% | 22.2%          | 75% (1 y) 58.3% (3 y) |
| Marrone 35   | 2017             | 1987-2015        | 23             | 17.6 (11-33) | 4.3% | 17.4%          | 78% (1 y) |
| Serfas 14    | 2020             | 2010-2018        | 537#           | 14 (10-18) | 51%  | 7.6%           | Not reported |
| Hernandez 36 | 2020             | 2004-2014        | 93*           | 24 (21-40) | Not reported | 26.3% | Not reported |

(Continued)
TABLE 1. Continued

| First author | Publication year | Study time frame | Fontan patients | Age (y) | HLHS | Early mortality | Long-term survival |
|--------------|------------------|-----------------|----------------|---------|------|----------------|-------------------|
| Riggs49      | 2021             | 2006-2017       | 1301          | 6 (4-11) | Not reported for Fontan patients | Not reported | all HLHS: 85% (1 y) 76% (5 y) Fontan: 85% (1 y) 80% (5 y) |

HLHS, Hypoplastic left heart syndrome; NA, not available. *Multi-Institutional Pediatric Heart Transplant Study. | Nationwide Inpatient Sample data from the United States. This study included patients with single ventricle age 14 y and older. The authors were unable to determine whether all of those patients had undergone Fontan completion or remained in an intermediate palliated state. | Meta-analysis. ¶Pediatric Heart Transplant Study database. §Society of Thoracic Surgeons Congenital Heart Surgery Database. **Nationwide Inpatient Sample database. | United Network for Organ Sharing database and Pediatric Health Information System.

A multidisciplinary team meeting should be held before surgery and include members from the surgical, cardiology, intensive care, and hematology teams. It is critical to plan for considerable bleeding after extensive dissection, especially in the context of prolonged bypass time and hypothermia. It is most crucial to ensure timely availability of blood products and other hemostatic adjuncts.

The timing of the recipient and donor procedures is most crucial to avoid unnecessary ischemic time for the donor heart. In our unit, patients are transferred to the operating room to allow 4 hours for surgical reconstruction before the donor heart arrival. Thus, precise coordination and close communication with the transplanting team is a must, because organ procurement must be delayed until the transplant team approves such procurement. The paramount importance of meticulous coordination between the transplant team and procurement team cannot be overemphasized. For patients with a bilateral superior vena cava, it is advantageous to bring a long segment of superior vena cava including the innominate vein because this facilitates reimplantation.20 However, in patients with azygos continuation of the inferior vena cava, an innominate vein reimplantation with a large graft before donor heart arrival may be required.

OUTCOMES

Varying outcomes have been reported from single centers and larger databases after transplantation of this challenging group of patients. The recent studies are summarized in Table 1. There is a striking inconsistency in reporting the outcomes. Namely, some report the overall outcomes of transplantation in patients with CHD, mentioning the number of patients with Fontan circulation, yet do not mention the outcomes in the latter. Furthermore, even when the results are described specifically for Fontan patients, the outcomes of those with HLHS and others are not separated. The complexity for those who had Norwood-type reconstruction of the aorta is greater compared with those who did not, that is, in whom the ascending aorta could be crossclamped.

The main causes of hospital mortality after heart transplantation are infection and graft failure.30,31 The long-term survival in the modern era appears to be good. For instance, patients from the Australian and New Zealand Fontan registry who underwent transplantation between 1990 and 2015 (n = 34) had a post-transplant survival of 91%, 78%, and 71% at 1, 5, and 10 years, respectively.3 These patients had similar long-term survival to other patients with CHD undergoing heart transplantation.1 We have previously demonstrated that patients with CHD had a higher 30-day mortality compared with patients without CHD, but similar survival after 10 years.25-26

Multiple studies have reported an early mortality ranging from 14% to 30%.2,5,12,31-36 Yet, we3,27 and others13 have demonstrated that an early mortality of 0% to 5.8%, and good long-term survival can be achieved in specialized institutions with appropriate expertise. A recent multi-institutional study that included 51% of patients with HLHS demonstrated an early mortality of 7.6%.14 Thus, there is mounting evidence to suggest that low operative mortality and good long-term results can be achieved in these challenging patients with a focused approach.

INDISCRIMINATE REPORTING OF THE OUTCOMES OF HEART TRANSPLANTATION AFTER FONTAN OPERATION

It is fascinating that the latest version of the STAT Mortality Scores and Categories assigns heart transplantation, regardless of the status of the recipient (ie, univentricular
or biventricular circulation, primary or redo), to the STAT 3 category.\(^3\)\(^7\) Addition of pulmonary artery reconstruction would put these patients into the STAT 4 category. However, the additional risk of aortic arch replacement after Norwood-type reconstruction is not accounted for, although it is likely that this would further contribute to complexity and risk. Heart transplantation as a primary procedure in a patient without any prior heart surgery is one of the easiest cardiac operations. Clearly, the complexity and the risk of heart transplantation would be very different in patients without prior heart surgery compared with heart transplantation after the Fontan operation in patients with HLHS. Moreover, even in patients with Fontan circulation, the complexity of heart transplantation in those with and without prior aortic arch reconstruction is considerably different. Therefore, the operative mortality after heart transplantation in Fontan patients with and without prior aortic arch reconstruction should be reported separately to allow for appropriate risk stratification.

ACCESS TO TRANSPLANTATION

An analysis of the Australia and New Zealand Fontan registry has shown that 2.5% of patients with Fontan circulation underwent transplantation at 20 years, whereas there was a higher rate of patients with Fontan failure.\(^3\)\(^3\)\(^8\) Furthermore, evaluation of referral patterns revealed that patients who were not followed up at the national referral center were less likely to be considered for transplantation.\(^3\) Patients with failing Fontan circulation require early referral for transplant evaluation to a center of excellence where they can be assessed for all available surgical treatment options and listed in time for transplantation, before becoming high-risk candidates. We have previously demonstrated the cost-effectiveness of the centralized national pediatric heart transplantation program in Australia.\(^3\)\(^9\) Although direct comparison is difficult, the study suggested that the cost-utility of pediatric heart transplantation in Australia appeared more favorable than that reported in the United States.\(^3\)\(^9\) Furthermore, the positive relationship between increasing operative volume and improved outcomes in heart transplantation has been documented.\(^3\)\(^0\)\(^4\)\(^2\) In particular, an increased mortality has been observed for centers performing fewer than 10 to 14 heart transplantsations per year.\(^3\)\(^0\)\(^4\)\(^2\) In the United States, a theoretical regionalization simulation appears to be associated with improved mortality after heart transplantation.\(^3\)\(^1\) Although there are currently no data available to support this notion, one would expect that such reduction in mortality can only be amplified in high-risk patients with failing Fontan circulation. It should also be remembered that a low-volume center, without highly specialized expertise in congenital heart disease, patients with failing complex Fontan circulation may be labeled as inoperable, limiting their access to heart transplantation. Needless to say, regionalization is a complex issue,\(^3\)\(^2\) yet traveling to a higher-volume center to improve survival sounds like a small price to pay.

CONCLUSIONS

Heart transplantation in the ever-increasing population of patients with failed Fontan circulation is a complex issue. It appears that many patients with failed Fontan circulation may be denied heart transplantation because of a perceived impermissibly high risk of surgery due to its complexity and apparent multiorgan failure. Current literature is lacking risk-stratified reporting of the outcomes of heart transplant recipients with failing Fontan circulation.

Conflict of Interest Statement

The authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

References

1. d’Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, et al. Redefining expectations of long-term survival after the Fontan procedure twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation. 2014;130:S32-8.
2. Voelker RK, Epstein DJ, Guthrie TJ, Gandhi SK, Canter CE, Haddison CB. Trends in the indications and survival in pediatric heart transplants: a 24-year single-center experience in 307 patients. Ann Thorac Surg. 2012;94:807-16.
3. Shi WY, Yong MS, McGiffin DC, Jain P, Raygrok PN, Marasco SF, et al. Heart transplantation in Fontan patients across Australia and New Zealand. Heart. 2016;102:1120-6.
4. Simpson KE, Cibulka N, Lee CK, Haddison CH, Canter CE. Failed Fontan heart transplant candidates with preserved vs impaired ventricular ejection: 2 distinct patient populations. J Heart Lung Transpl. 2012;31:545-7.
5. Murtaza B, Hermuzi A, Crossland DS, Parry G, Lord S, Hudson M, et al. Impact of mode of failure and end-organ dysfunction on the survival of adult Fontan patients undergoing cardiac transplantation. Eur J Cardiothorac Surg. 2017;51:135-41.
6. Davies RR, Chen JM, Mosca RS. The Fontan procedure: evolution in technique; attendant imperfections and transplantation for “failure.” Semin Thorac Cardiovasc Surg Pediatr Card Surg Ana. 2011;14:55-66.
7. Jaquiss RD, Aziz H. Is four stage management the future of univentricular hearts? destination therapy in the young. Semin Thorac Cardiovasc Surg Pediatr Card Surg Ana. 2016;19:30-4.
8. Woods RK, Hraska V. Commentary: lymphatic fluid flows uphill in both hemispheres—and leaks in the same places. J Thorac Cardiovasc Surg. 2021;161:2166-7.
9. d’Udekem Y, Xu MY, Galati JC, Lu S, Iyengar AJ, Konstantinov IE, et al. Predictors of survival after single-ventricle palliation: the impact of right ventricular dominance. J Am Coll Cardiol. 2012;59:1178-85.
10. Lamour JM, Kanter KR, Nafiel DC, Chriasmt MR, Morrow WR, Clemson BS, et al. Cardiac transplant registry database: pediatric heart transplant study. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol. 2009;54:160-5.
11. Jayakumar KA, Addonizio LJ, Kichuk-Chriast MR, Galantowicze M, Lamour JM, Quaegebeur JM, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol. 2004;44:2065-72.
12. Davies RR, Sorabella RA, Yang J, Mosca RS, Chen JM, Quaegebeur JM. Outcomes after transplantation for “failed” Fontan: a single-institution experience. J Thorac Cardiovasc Surg. 2012;143:1183-92.
13. Kanter KR, Mahle WT, Vincent RN, Berg AM, Kogon BE, Kirshbom PM. Heart transplantation in children with a Fontan procedure. Ann Thorac Surg. 2011;91: 823-30.
14. Serfas JD, Thibault D, Andersen ND, Chiswell K, Jacobs JP, Jacobs ML, et al. The evolving surgical burden of Fontan failure: an analysis of the Society of Thoracic Surgeons congenital heart surgery database. Ann Thorac Surg. 2021;112:179187.

15. Shi WY, Rouse M, Weintraub RG, Zannino D, Shipp A, d.

16. Buratto E, Shi WY, Ye XT, Konstantinov IE. Ventricular assist devices for the failing univentricular circulation. Expert Rev Med Devices. 2017;14:449-59.

17. Konstantinov IE, Buratto E, d’Udelem Y. Annuloplasty for aortic regurgitation in univentricular heart on ventricular assist support. Ann Thorac Surg. 2021;112:e65-7.

18. Chen S, Rosenfeld DN, Murray J, Dykes JC, Almond CS, Ylaragadda VV, et al. Bridge to transplant with ventricular assist device support in pediatric patients with single ventricle heart disease. ASAIO J. 2020;66:205-11.

19. Sanga D, Hollander SA, Vaikunth S, Haeefele C, Bensen R, Navarain M, et al. Comparison of combined heart – liver vs heart-only transplantation in pediatric and young adult Fontan recipients. J Heart Lung Transplant. 2021;40:298-306.

20. Reardon LC, Lin JP, Van Arsdell GS, Kaldas FM, Lluri G, Tan W, et al. Orthotopic heart and combined heart liver transplantation: the ultimate treatment option for failing Fontan physiology. Cureus Rep. Transplant. 2021;1:1-12.

21. Moosmann J, Dittrich S, Parbojo A, Cesnjevar R. RVAD implantation in a Fontan patient with protein-losing enteropathy as a bridge to transplant: Prêtre modifications. J Card Surg. 2020;35:1721-4.

22. Prêtre R, Hausssler A, Bettes D, Genoni M. Right-sided univentricular cardiac assistance in a failing Fontan circulation. Ann Thorac Surg. 2008;86:1018-20.

23. Konstantinov IE, McNeil K, Yeung S, Fawcett J, Mullany D, Dunning J. Fast track recovery following an block heart-lung-artery transplant in a patient with cystic fibrosis complicated by severe portal hypertension. Heart Lung Circ. 2008;17:154-6.

24. Iyengar AJ, Sharma VJ, Dudekem T, Konstantinov IE. Aortic arch and pulmonary artery reconstruction during heart transplantation after failed Fontan procedure. Interact Cardiovasc Thorac Surg. 2014;18:693-4.

25. Shi WY, Saxena P, Yong MS, Marasco SF, McGiffin DC, Sipp A, et al. Increasing complexity of heart transplantation in patients with congenital heart disease. Semin Thorac Cardiovasc Surg. 2016;28:487-97.

26. Blitzer D, Nguyen S, Farooqi KM, Takeda K. Orthotopic heart transplantation and concomitant aortic arch replacement in an adult Fontan patient with hypoplastic left heart syndrome. Interact Cardiovasc Thorac Surg. 2021;32:325-7.

27. Iyengar AJ, Sharma VJ, Weinstaeb RG, Sipp A, Bizzard CP, Konstantinov IE. Surgical strategies to facilitate heart transplantation in children after failed univentricular palliations: the role of advanced intraoperative surgical preparation. Eur J Cardiothorac Surg. 2014;46:480-5.

28. Brink J, Saxena P, Yong MS, McGiffin D. Pulmonary artery reconstruction with donor aortic homograft during cardiac transplantation in the failed Fontan circulation. J Card Surg. 2016;31:65-8.

29. Menkis AH, McKenzie FN, Novick RJ, Kostuk WJ, Pfuefgelder PW, Goldbach M, et al. Expanding applicability of transplantation after multiple prior palliative procedures. The paediatric heart transplant group. Ann Thorac Surg. 1991;52:722-6.

30. Bernstein D, Naftel D, Chin C, Addonizio LJ, Gamberg P, Blume ED, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation. 2006;114:273-80.

31. Michielsen G, van Melle JP, Woffl D, Di Carlo D, Jacobs JP, Mattila IP, et al. Favorable mid-term outcome after heart transplantation for late Fontan failure. Eur J Cardiothorac Surg. 2015;47:665-71.

32. Gamba A, Merlo M, Fiocchi R, Terzi A, Mammana C, Sebastiani R, et al. Heart transplantation in patients with previous Fontan operations. J Thorac Cardiovasc Surg. 2004;127:555-62.

33. Tabarsi N, Guan M, Simmonds J, Toma M, Kiess M, Tsang V, et al. Meta-analysis of the effectiveness of heart transplantation in patients with a failing Fontan. Am J Cardiol. 2017;119:1269-74.

34. Berg CJ, Bauer BS, Hageman A, Aboulhosn JA, Reardon LC. Mortality risk stratification in Fontan patients who underwent heart transplantation. Am J Cardiol. 2017;119:1675-9.

35. Marcone C, Ferrero P, Ursicchio N, Sebastiani R, Vittori C, Ciuffreda M, et al. The unnatural history of failing univentricular hearts: outcomes up to 25 years after heart transplantation. Interact Cardiovasc Thorac Surg. 2017;25:892-7.

36. Hernandez GA, Lemor A, Clark D, Blumer V, Burstein D, Byrne R, et al. Heart transplantation and in-hospital outcomes in adult congenital heart disease patients with Fontan: a decade nationwide analysis from 2004 to 2014. J Card Surg. 2020;35:603-8.

37. Jacobs ML, Jacobs JP, Thibault D, Hill KD, Anderson BR, Eghtesady P, et al. Up-dating an empirically based tool for analyzing congenital heart surgery mortality. World J Pediatr Congenit Heart Surg. 2021;12:246-81.

38. Sharma VJ, Iyengar AJ, Zannino D, Gentles T, Justo R, Cuelmijan DS, et al. Protein-losing enteropathy and plastic bronchiolitis after the Fontan procedure. J Thorac Cardiovasc Surg. 2021;161:2158-65.

39. Ye XT, Parker A, Brink J, Weintraub RG, Konstantinov IE. Cost-effectiveness of the national pediatric heart transplantation program in Australia. J Thorac Cardiovasc Surg. 2019;157:1158-66.e2.

40. Petit SJ, Hjord PS, Hawkins NM, Gardner RS, Haj-Yahia S, McMurray JJ, et al. How small is too small? A systematic review of center volume and outcome after cardiac transplantation. Circ Cardiovasc Qual Outcomes. 2012;5:783-90.

41. Khoo A, Weiss ES, Yah DD, Shah AS, Cameron DE, Baumgartner WA, et al. Instrumental factors beyond procedural volume significantly impact center variability in outcomes after orthotopic heart transplantation. Ann Surg. 2012;256:616-23.

42. Weiss ES, Meguid RA, Patel ND, Russell SD, Shah AS, Baumgartner WA, et al. Increased mortality at low-volume orthotopic heart transplantation centers: should current standards change? Ann Thorac Surg. 2008;86:1250-60.

43. Magruder JT, Shah AS, Crawford TC, Grimm JC, Kim B, Orens JB, et al. Simulated regionalization of heart and lung transplantation in the United States. Am J Transplant. 2017;17:485-95.

44. Subramanian MP, Yang Z, Chang SH, Puri V. Regionalization for thoracic surgery: economic implications of regionalization in the United States. J Thorac Cardiovasc Surg. 2021;161:1705-9.

45. Kazamplou T, Diggis BS, Welke K, Tibayan F, Gelow J, Guyton SW, et al. Impact of single-ventricle physiology on death after heart transplantation in adults with congenital heart disease. Ann Thorac Surg. 2012;94:1281-7.

46. Backer CL, Russell HM, Palh E, Monge MC, Gambetta K, Kindel SJ, et al. Heart transplantation for the failing Fontan. Ann Thorac Surg. 2013;96:1413-9.

47. Miller JR, Simpson KE, Epstein DJ, Lancaster TS, Henn MC, Schuessler RB, et al. Improved survival after heart transplant for failed Fontan patients with preserved ventricular function. J Heart Lung Transplant. 2016;35:877-83.

48. Simpson KE, Pratc J, Kirkln JK, Naftel DC, Singh RK, Edens RE, et al. Fontan patient survival after pediatric heart transplantation has improved in the current era. Ann Thorac Surg. 2017;103:1315-20.

49. Riggs KW, Broderick JT, Price N, Chin C, Zafar F, Morales DLS. Transplantation for congenital heart disease: focus on the impact of functionally univentricular versus biventricular circulation. World J Pediatr Congenit Heart Surg. 2021;12:352-9.

Key Words: Fontan, single ventricle, transplantation
Heart Transplantation After Fontan Operation: Recent Articles From AATS Journals

**JTCVS**: Protein-losing enteropathy and plastic bronchitis after the Fontan procedure. Sharma VJ, Iyengar AJ, Zannino D, Gentles T, Justo R, Celermajer DS, Bullock A, Winlaw D, Wheaton G, Burchill L, Cordina R, d’Udekem Y. J Thorac Cardiovasc Surg. 2021;161(6):2158-2165.

**Commentary**: Late adverse outcomes of the Fontan circulation: A PLEa for standardization of diagnostic criteria. Lubert AM, Redington AN. J Thorac Cardiovasc Surg. 2021;161(6):2167-2168.

**Commentary**: Lymphatic fluid flows uphill in both hemispheres—and leaks in the same places. Woods RK, Hraska V. J Thorac Cardiovasc Surg. 2021;161(6):2166-2167.

**JTCVS**: Cost-effectiveness of the National Pediatric Heart Transplantation Program in Australia. Ye XT, Parker A, Brink J, Weintraub RG, Konstantinov IE. J Thorac Cardiovasc Surg. 2019;157(3):1158-1166.

**Commentary**: Buy or sell: Pediatric cardiac transplantation is still a societal bull market...for now. Evers PD, Morales D. J Thorac Cardiovasc Surg. 2019;157(3):1167.

**JTCVS**: Regionalization for thoracic surgery: Economic implications of regionalization in the United States. Subramanian MP, Yang Z, Chang SH, Puri V. J Thorac Cardiovasc Surg. 2021;161(5):1705-1709.

**Commentary**: Go big or stay home? Chilakamarry S, Boffa DJ. J Thorac Cardiovasc Surg. 2021;161(5):1711-1712.

**Commentary**: Regionalization for every region? Fernandez FG. J Thorac Cardiovasc Surg. 2021;161(5):1710.